Corbion N.V.

ENXTAM:CRBN 株式レポート

時価総額：€1.1b

Corbion 過去の業績

過去 基準チェック /46

Corbionの収益は年間平均-11.1%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間12.2% 4.5%割合で 増加しています。 Corbionの自己資本利益率は10.1%であり、純利益率は5.9%です。

主要情報

-11.08%

収益成長率

-10.79%

EPS成長率

Chemicals 業界の成長1.60%
収益成長率4.46%
株主資本利益率10.07%
ネット・マージン5.90%
次回の業績アップデート31 Jul 2026

最近の業績更新

Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point

Mar 26
Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point

Recent updates

CRBN: Special Dividend And Execution On Margins Will Support Upside Potential

The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.

CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk Balance

Analysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.

CRBN: Higher Margins And Special Dividend Will Support Future Re Rating

Analysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.

CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic Outlook

Analysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).

CRBN: Higher Future P/E Assumptions Will Support A More Optimistic Outlook

Analysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.

CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued Shares

Analysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.

CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 Outlook

Narrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Jan 14
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 Outlook

Analysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.

CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted Demand

Analysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.

CRBN: Margin Improvements And Buybacks Will Support A Future Re-Rating

Analysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.

Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value Estimate

Nov 14
Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value Estimate

Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share Price

Jun 23
Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

May 07
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?

Apr 10
At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?

Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point

Mar 26
Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point
User avatar

Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success

Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.

Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of Return

Feb 28
Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of Return

Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)

Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Nov 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued

Oct 31
An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued

Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt

Sep 26
Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Corbion N.V. (AMS:CRBN)

Jul 18
The Price Is Right For Corbion N.V. (AMS:CRBN)

Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate

Jun 20
Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate

Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

May 08
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely

Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?

Apr 17
Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?

Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking

Jan 20
Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Dec 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)

Nov 04
Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)

Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet

Sep 13
Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet

Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)

Aug 04
Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)

When Should You Buy Corbion N.V. (AMS:CRBN)?

Jul 14
When Should You Buy Corbion N.V. (AMS:CRBN)?

Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate

Jun 04
Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate

Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden

Apr 21
Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden

Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56

Mar 10
Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56

Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?

Feb 22
Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?

Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business

Jan 26
Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business

Is Corbion (AMS:CRBN) Using Too Much Debt?

Dec 20
Is Corbion (AMS:CRBN) Using Too Much Debt?

Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)

Nov 24
Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)

Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Nov 09
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?

Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively

Oct 08
Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively

Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden

Sep 19
Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden

A Look At The Intrinsic Value Of Corbion N.V. (AMS:CRBN)

Aug 23
A Look At The Intrinsic Value Of Corbion N.V. (AMS:CRBN)

収支内訳

Corbion の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ENXTAM:CRBN 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
31 Dec 251,2677517443
30 Sep 251,2827017844
30 Jun 251,2976618245
31 Mar 251,2925618245
31 Dec 241,2884618346
30 Sep 241,2744818046
30 Jun 241,2605017745
31 Mar 241,2624717645
31 Dec 231,2644317646
30 Sep 231,3384817847
30 Jun 231,4125418048
31 Mar 231,4357217648
31 Dec 221,4589017147
30 Sep 221,3507616746
30 Jun 221,2436316246
31 Mar 221,1577015844
31 Dec 211,0717815543
30 Sep 211,0409714941
30 Jun 211,01011614440
31 Mar 219989514238
31 Dec 209877314037
30 Sep 209924914335
30 Jun 209972414732
31 Mar 209872514733
31 Dec 199762614635
30 Sep 199533714138
30 Jun 199304813542
31 Mar 199145113241
31 Dec 188975412939
30 Sep 188836112837
30 Jun 188696912635
31 Mar 188807712634
31 Dec 178928512633
30 Sep 179058712832
30 Jun 179188913032
31 Mar 179149512831
31 Dec 1691110212631
30 Sep 1691710312433
30 Jun 1692210412234
31 Mar 169209112233
31 Dec 159187812133
30 Sep 158854511932
30 Jun 158511311831

質の高い収益: CRBNは 高品質の収益 を持っています。

利益率の向上: CRBNの現在の純利益率 (5.9%)は、昨年(3.6%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CRBNの収益は過去 5 年間で年間11.1%減少しました。

成長の加速: CRBNの過去 1 年間の収益成長率 ( 63% ) は、5 年間の平均 ( 年間-11.1%を上回っています。

収益対業界: CRBNの過去 1 年間の収益成長率 ( 63% ) はChemicals業界32.3%を上回りました。

株主資本利益率

高いROE: CRBNの 自己資本利益率 ( 10.1% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/04/30 18:31
終値2026/04/30 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Corbion N.V. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13

アナリスト機関
Setu ShardaBarclays
Sebastian BrayBerenberg
Fintan RyanBerenberg